John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
John DiPersio, MD, PhD, chief of the Division of Oncology and director, Siteman Cancer Center, University of Washington School of Medicine, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibodydrug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
In the current landscape, the available targeted therapies are given to any patient with acute myeloid leukemia (AML), regardless of whether they express what the drug is targeting. This is because the early-stage studies tend to include a broader patient population as the investigators are interested in understanding what occurs when a patient’s expression to the antigen is non-existent, low, or high. This will answer the question of which patients are the appropriate patients for targeted AML therapies. Oncologists are still unsure of this, DiPersio says.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More